Terms ending in 2037
Every in-force patent on Adma Biomanufacturing, LLC's record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,259,865 | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection In force · High confidence | Adma Biomanufacturing, LLC | In force | High confidence | |
| US 11,084,870 | Anti-Pneumococcal Hyperimmune Globulin for the Treatment and Prevention of Pneumococcal Infection In force · High confidence | Adma Biomanufacturing, LLC | In force | High confidence | |
| US 12,612,450 | Anti-Pneumococcal Hyperimmune Globulin for the Treatment and Prevention of Pneumococcal Infection In force · High confidence | Adma Biomanufacturing, LLC | In force | High confidence | |
| US 11,897,943 | Anti-Pneumococcal Hyperimmune Globulin for the Treatment and Prevention of Pneumococcal Infection In force · High confidence | Adma Biomanufacturing, LLC | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.